Literature DB >> 20399083

Increased levels of microparticles originating from endothelial cells, platelets and erythrocytes in subjects with metabolic syndrome: relationship with oxidative stress.

O Helal1, C Defoort, S Robert, C Marin, N Lesavre, J Lopez-Miranda, U Risérus, S Basu, J Lovegrove, J McMonagle, H M Roche, F Dignat-George, D Lairon.   

Abstract

BACKGROUND AND AIMS: The Metabolic Syndrome (MetS) is associated with increased cardiovascular risk. Circulating microparticles (MP) are involved in the pathogenesis of atherothrombotic disorders and are raised in individual with CVD. We measured their level and cellular origin in subjects with MetS and analyzed their associations with 1/anthropometric and biological parameters of MetS, 2/inflammation and oxidative stress markers. METHODS AND
RESULTS: Eighty-eight subjects with the MetS according to the NCEP-ATPIII definition were enrolled in a bicentric study and compared to 27 healthy controls. AnnexinV-positive MP (TMP), MP derived from platelets (PMP), erythrocytes (ErMP), endothelial cells (EMP), leukocytes (LMP) and granulocytes (PNMP) were determined by flow cytometry. MetS subjects had significantly higher counts/μl of TMP (730.6±49.7 vs 352.8±35.6), PMP (416.0±43.8 vs 250.5±23.5), ErMP (243.8±22.1 vs 73.6±19.6) and EMP (7.8±0.8 vs 4.0±1.0) compared with controls. LMP and PNMP were not statistically different between groups. Multivariate analysis demonstrated that each criterion for the MetS influenced the number of TMP. Waist girth was a significant determinant of PMP and EMP level and blood pressure was correlated with EMP level. Glycemia positively correlated with PMP level whereas dyslipidemia influenced EMP and ErMP levels. Interestingly, the oxidative stress markers, plasma glutathione peroxydase and urinary 8-iso-prostaglandin F(2) α, independently influenced TMP and PMP levels whereas inflammatory markers did not, irrespective of MP type.
CONCLUSION: Increased levels of TMP, PMP, ErMP and EMP are associated with individual metabolic abnormalities of MetS and oxidative stress. Whether MP assessment may represent a marker for risk stratification or a target for pharmacological intervention deserves further investigation.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20399083     DOI: 10.1016/j.numecd.2010.01.004

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  30 in total

Review 1.  Microparticles and cardiovascular diseases.

Authors:  Christos Voukalis; Eduard Shantsila; Gregory Y H Lip
Journal:  Ann Med       Date:  2019-06-17       Impact factor: 4.709

Review 2.  Circulating membrane-derived microvesicles in redox biology.

Authors:  Michael Craig Larson; Cheryl A Hillery; Neil Hogg
Journal:  Free Radic Biol Med       Date:  2014-04-18       Impact factor: 7.376

3.  Microparticles variability in fresh frozen plasma: preparation protocol and storage time effects.

Authors:  Anastasios G Kriebardis; Marianna H Antonelou; Hara T Georgatzakou; Vassilis L Tzounakas; Konstantinos E Stamoulis; Issidora S Papassideri
Journal:  Blood Transfus       Date:  2016-02-22       Impact factor: 3.443

4.  Increased circulating microparticles in streptozotocin-induced diabetes propagate inflammation contributing to microvascular dysfunction.

Authors:  Qilong Feng; Christian J Stork; Sulei Xu; Dong Yuan; Xinghai Xia; Kyle B LaPenna; Ge Guo; Haoyu Sun; Li-Chong Xu; Christopher A Siedlecki; Kathleen M Brundage; Nate Sheaffer; Todd D Schell; Pingnian He
Journal:  J Physiol       Date:  2019-01-09       Impact factor: 5.182

5.  Association between heme oxygenase-1 gene promoter polymorphisms and metabolic syndrome in Iranians.

Authors:  Shaghayegh Haghjooy Javanmard; Kiandokht Keyhanian; Parisa Loghmani; Amir Abbas Samety; Faraidoon Haghdoost; Laleh Rafiei; Mohammad Talaei; Sedigheh Asgari; Mohammad Hashemi Jazi; Nizal Sarrafzadegan
Journal:  Mol Biol Rep       Date:  2011-07-03       Impact factor: 2.316

Review 6.  Microvesicles at the crossroads between infection and cardiovascular diseases.

Authors:  Jing Xiong; Virginia M Miller; Yunman Li; Muthuvel Jayachandran
Journal:  J Cardiovasc Pharmacol       Date:  2012-02       Impact factor: 3.105

Review 7.  Blood Cell-Derived Microvesicles in Hematological Diseases and beyond.

Authors:  Hara T Georgatzakou; Sotirios P Fortis; Effie G Papageorgiou; Marianna H Antonelou; Anastasios G Kriebardis
Journal:  Biomolecules       Date:  2022-06-08

8.  Dynamics of circulating microparticles in obesity after weight loss.

Authors:  Elena Campello; Eva Zabeo; Claudia M Radu; Luca Spiezia; Mirto Foletto; Luca Prevedello; Sabrina Gavasso; Cristiana Bulato; Roberto Vettor; Paolo Simioni
Journal:  Intern Emerg Med       Date:  2016-02-02       Impact factor: 3.397

9.  Microvesicles/exosomes as potential novel biomarkers of metabolic diseases.

Authors:  Günter Müller
Journal:  Diabetes Metab Syndr Obes       Date:  2012-08-07       Impact factor: 3.168

10.  The origin of circulating CD36 in type 2 diabetes.

Authors:  M J Alkhatatbeh; A K Enjeti; S Acharya; R F Thorne; L F Lincz
Journal:  Nutr Diabetes       Date:  2013-02-04       Impact factor: 5.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.